ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Synergistic Activation of Immunogenic Cell Death and the cGAS-STING Pathway by Engineered Zinc/Manganese-Based Metal-Organic Framework Nanoplatforms for Colon Cancer Immunotherapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Manganese-Chlorella Hydrogel for an Integrated "Remove-Remodel-Repair" Strategy in Pancreatic Cancer Therapy.Nano-micro letters · 2026Article
- Cholesterol-depleting nanozyme amplifies membrane-diffusive ferroptosis for potentiating anti-tumor immunity in colorectal cancer.Journal of materials science. Materials in medicine · 2026Article
- The mitochondrial DNA-cGAS-STING axis in colorectal cancer: a focused review of context-dependent roles and therapeutic opportunities.Frontiers in molecular biosciences · 2026Review
- Metal-Organic Framework-Based and Metal-Organic Framework-Derived Nanomaterials for Cancer Theranostics and Antibacterial Applications: Advances, Challenges, and Perspectives.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase-stimulator of interferon genes (cGAS-STING) pathway is crucial for tumor immunity. However, activation of the cGAS-STING pathway alone is seldom sufficient to eliminate established tumors. Here, we report the engineering of zinc/manganese (Zn/Mn)-based metal-organic framework (MOF) nanoparticles, that is, AMP@Zn/Mn-MOF, comprising Zn/Mn-MOF nanoparticles as the carrier and the STING agonist c-di-AMP diammonium as the therapeutic drug for reinforcing antitumor immune responses. These therapeutic nanoplatforms can significantly activate the cGAS‒STING pathway and facilitate the innate immune response. Furthermore, the peroxidase (POD)-mimetic and glutathione oxidase (GSHox)-mimetic activities of AMP@Zn/Mn-MOF can significantly potentiate tumor cell death and effectively induce robust immunogenic cell death (ICD), thereby amplifying the cGAS-STING pathway. Moreover, AMP@Zn/Mn-MOF reprogrammed the immunosuppressive tumor microenvironment by promoting intratumoral lymphocyte infiltration, thereby significantly suppressing the growth of murine MC38 tumors in mice. Notably, AMP@Zn/Mn-MOF amplified the therapeutic effect of anti-programmed death ligand 1 (αPD-L1) blockade by triggering systemic antitumor responses, resulting in a notable abscopal effect to effectively inhibit distant tumors. In summary, AMP@Zn/Mn-MOF offers a nanoplatform with enhanced antitumor effectiveness through activation of the cGAS-STING pathway and ICD, suggesting that enhanced immune checkpoint blockade-based immunotherapy is promising for colon cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.